LPAR3 (lysophosphatidic acid receptor 3) is a G protein-coupled receptor that binds lysophosphatidic acid (LPA) and mediates diverse cellular signaling pathways through Gi/Go and Gq protein coupling 1. The receptor activates calcium signaling via the Gq/PLC pathway and regulates chloride transport through calcium-activated chloride channels in ocular surface epithelial cells 1. LPAR3 plays significant roles in cancer progression, promoting epithelial-mesenchymal transition and angiogenesis in nasopharyngeal carcinoma in response to matrix stiffness 2, and enhancing proliferation in malignant peripheral nerve sheath tumors while LPAR1 mediates migration 3. In liver disease, TEAD4-mediated upregulation of LPAR3 promotes hepatic stellate cell activation and fibrosis through p38 MAPK and PI3K/AKT signaling pathways 4. Therapeutically, LPAR3 shows protective effects in knee osteoarthritis, where lipoxin A4 activates the ESR2/LPAR3/Nrf2 axis to inhibit ferroptosis in fibroblast-like synoviocytes 5. The receptor is aberrantly expressed in various cancers including osteosarcoma, where it is regulated by ceRNA networks 6, and oral squamous cell carcinoma via circular RNA mechanisms 7. LPAR3 also contributes to macrophage polarization and anti-tumor immune responses in colorectal cancer 8.